---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-152380"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:52:56.337631+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# WTX-124 Phase 1/1b shows 3 objective responses (1 CR) in checkpoint-refractory solid tumors

## Summary
- 3 objective responses out of 35 monotherapy-treated patients: 1 confirmed complete response, 2 partial responses.
- All responding patients had 100% target lesion regression; responses durable at recommended dose for expansion (RDE).
- RDE selected as 18 mg IV every 2 weeks; three expansion arms opened in RCC, melanoma, cutaneous SCC.
- WTX-124 + pembrolizumab combination well-tolerated with enhanced T-cell activation in tumors; no new safety signals.
- Company plans to engage regulators on potential monotherapy accelerated approval pathway.

## SEC filing metadata
- accession: 0001193125-24-152380
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312524152380/0001193125-24-152380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312524152380/d800910d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-152380
- JSON: https://secwatch.observer/filing/0001193125-24-152380.json
- Plain text: https://secwatch.observer/filing/0001193125-24-152380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.